HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.
Betül AltunayAgnieszka MorgenrothMohsen BeheshtiAndreas VoggNicholas C L WongHong Hoi TingHans-Jürgen BiersackElmar StickelerFelix Manuel MottaghyPublished in: European journal of nuclear medicine and molecular imaging (2020)
While monoclonal antibodies are well established drug delivery vehicles, the current literature on molecular imaging supports the notion that antibody fragments, such as affibodies or nanobodies, might be superior in this approach.